Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Inclusion Criteria: * Subjects will be males or females of any ethnic origin between 18 and 65 years of age and with a body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive. * Female subjects must be of non-childbearing potential, and are defined as follows: Female subjects 50 years of age or less must be surgically sterile or post-menopausal (defined as at least two years post cessation of menses and/or follicular stimulating hormone \>40 mIU/mL and serum oestradiol \<110 pmol/L). Female subjects of more than 51 years of age must be surgically sterile or post-menopausal (defined by a value of follicular stimulating hormone \>40 mIU/mL and no spontaneous menstruation for at least one year before the first dose). * Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations. * Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions. Exclusion Criteria: * Male subjects who are not willing, or whose partners are not willing, to use appropriate contraception (such as condom with spermicidal foam/gel/film/cream/suppository) from the time of the first dose until 3 months after the final dosing occasion. * Subjects who have received any prescribed systemic or topical medication within 14 days (or corticosteroids within 4 weeks) of the first dose administration (for female subjects, stable hormone replacement …